Pruritus Relief thru Itch-Scratch Modulation (“PRISM”) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks […]
New Haven, CT, March 21, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine®
Highly experienced clinical drug developer to oversee R&D functions and Company’s Phase 3 development program New Haven, CT, October 12,
Company continuing the development of Nalbuphine® ER in chronic pruritus conditions New Haven, CT, July 20, 2017 – Trevi Therapeutics,
